After lengthy application processes, the intellectual property rights for the MedSked label sleeve have been formally recognized by Canada and Mexico, which become the first two countries outside the United States to patent MedSked’s unique medication adherence capabilities.
Canada is one of over 30 countries where MedSked was used to support clinical trials. But because of the close relationship between the U.S., Canada and Mexico, the executive management of Med-Con Technologies (which owns and markets the MedSked and MedCon Mobile Smart Label product lines) decided to make the significant effort to obtain patents in these countries.
“Our U.S. pharma clients do many clinical trials in Canada,” said Thomas Guarnera, marketing manager for Med-Con Technologies. “It was important for us to be proactive and protect our brand in both countries.”
The new patent also plays a role in Med-Con Technologies’ plans to directly market its medication adherence solution to the Canadian pharma industry. “Our patent speaks to MedSked’s credibility, our years of development and testing,”said Guarnera," As importantly, it helps make a statement to pharma companies in Canada: We are committed to your country, and you can count on MedSked as a reliable business partner.”